Medrol Dosepak for Outpatient Total Knee Arthroplasty

Launched by RUSH UNIVERSITY MEDICAL CENTER · Oct 18, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called methylprednisolone, which is taken by mouth, on pain and recovery after total knee replacement surgery (also known as total knee arthroplasty). The researchers want to find out if taking this medication starting the day after surgery can help patients feel less pain, use fewer strong pain medications (opioids), experience less nausea, and have fewer complications during the first week after surgery. They also hope that patients who take methylprednisolone will have better recovery outcomes three to six weeks after their surgery compared to those who do not receive the medication.

To participate in this study, you need to be at least 18 years old and scheduled for a primary knee replacement surgery due to osteoarthritis. However, there are certain conditions that would prevent you from joining, such as having a history of chronic steroid use, certain infections, or other serious health issues. If you are eligible and decide to participate, you can expect to be randomly assigned to either receive the methylprednisolone or a placebo (a dummy pill with no active medication) for comparison. This trial is currently recruiting participants, and it aims to improve pain management and recovery for knee surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient undergoing primary TKA with a diagnosis of osteoarthritis
• • •≥ 18 years old
• • Willingness to undergo randomization
• Exclusion Criteria:
• • Reported chronic corticosteroid or opiate use
• • Suspected or confirmed periprosthetic joint infection
• • Revision TKA
• • Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, or post-traumatic arthritis
• • American Society of Anesthesiologists (ASA) score ≥ 4
• • Reported history of liver disease, renal disease, or diabetes mellitus
• • Current systemic fungal infection or other local infection
• • Immunocompromised or immunosuppressed
• • Current peptic ulcer disease
• • History of hypothyroidism, psychosis, heart failure, myasthenia gravis, ocular herpes simplex virus, or systemic sclerosis
• • Women with reported current pregnancy
• • Known hypersensitivity to methylprednisolone
• • •≤ 18 years old
• • Inability to take oral medications
• • Unable to provide consent